NICE backs Rinvoq for moderate active RA
11th October 2021 Uncategorised 0Decision expands access to oral therapy to around 27,000 people in England More: NICE backs Rinvoq for moderate active RA Source: News
read more
Decision expands access to oral therapy to around 27,000 people in England More: NICE backs Rinvoq for moderate active RA Source: News
read moreSamsung Biologics speeds $2B plant build forecast to boost capacity 70% jkeenan Fri, 10/08/2021 – 10:56 More: Samsung Biologics speeds B plant build forecast to boost capacity 70% Source: fierce
read moreChemoCentryx scores first FDA approval in 24-year history, and CEO Schall sees a blockbuster in the making kdunleavy Fri, 10/08/2021 – 10:35 More: ChemoCentryx scores first FDA approval in 24-year history, and CEO Schall sees a blockbuster in the making
read moreSanofi, GSK, Pfizer and Boehringer must face Zantac class-action lawsuits, court rules esagonowsky Fri, 10/08/2021 – 10:27 More: Sanofi, GSK, Pfizer and Boehringer must face Zantac class-action lawsuits, court rules Source: fierce
read moreAmgen’s latest Lumakras data in KRAS cancer underscore the bumpy road for combo strategy: analyst aliu Fri, 10/08/2021 – 10:05 More: Amgen's latest Lumakras data in KRAS cancer underscore the bumpy road for combo strategy: analyst Source: fierce
read moreA chemotherapy drug, NUC-7738, which is derived from a Himalayan fungus has been found to have 40 times greater potency in killing cancer cells than its original parent compound. More: Fungus-derived cancer killing drug by Oxford University shows promise Source:
read more© 1994 - 2026 B.M. Pharmaceuticals